Press releases
2021
20 October, 2021
Guard Therapeutics intends to carry out a capital raise of approximately SEK 180 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (THE “UNITED STATES”), AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE...
15 September, 2021
Guard Therapeutics reports positive results from phase 1b study
Guard Therapeutics today presents positive results from a clinical phase 1b study of the potentially kidney-protecting biological investigational drug ROSgard in connection with open heart surgery. The study fulfilled its primary objective – to confirm ROSgard’s favourable safety and tolerability profile in the patient population for which...
Guard Therapeutics AB (publ.) announces that the European Patent Office (EPO) today has granted a patent for the company’s biological investigational drug ROSgard, both as a product and for its medical use. The patent provides protection in Europe until 2037.
17 June, 2021
Last patient recruited to Guard Therapeutics’ phase 1b study of the investigational drug ROSgard
Guard Therapeutics announces today that all 12 patients have been included in the company’s clinical phase 1b study of ROSgard, which is being conducted in people undergoing open heart surgery who have additional risk factors for acute kidney injury. The study is being conducted at the University Hospital in Münster, Germany. Top-line results...
Guard Therapeutics today announces that the company has established an external Scientific Advisory Committee (SAC) initially consisting of five global experts. The committee’s main task in the near future will be to contribute their expertise in the final design of the planned phase 2 study of the company’s investigational drug ROSgard...